Lumigan just as effective as latanoprost/timolol combination

Article

Treatment with bimatoprost (Lumigan; Allergan) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost and timolol.

Treatment with bimatoprost (Lumigan; Allergan) alone is as effective at lowering intraocular pressure (IOP) as a fixed combination of latanoprost and timolol, according to the results of a study published in the December 2007 issue of Ophthalmology.

Luca Rossetti from the University of Milan, Italy and colleagues from centres in Germany, the United Kingdom, Greece and Switzerland enrolled 200 patients with glaucoma or ocular hypertension into a randomized, double-masked, multicentre clinical trial to compare the effect of bimatoprost and a fixed combination of latanoprost and timolol (LTFC) on 24-hour mean IOP.

Included in the study were patients who were controlled (IOP < 21 mmHg) on the non-fixed combination of latanoprost and timolol for at least three months before the baseline visit or patients on monotherapy with either latanoprost or timolol who were eligible for dual therapy not being fully controlled on monotherapy. The latter group of patients underwent a six-week wash-in phase with the non-fixed combination of latanoprost and timolol before baseline IOP determination and study inclusion. Supine and sitting position IOPs were recorded at 8 pm, midnight, 5 am, 8 am, noon and 4 pm at baseline, six week and 12 week follow-up.

Mean baseline IOPs were 16.3±3.3 mmHg and 15.5±2.9.mmHg in the bimatoprost and LTFC groups, respectively. At week 12, mean IOPs were 16.1±2.5 mmHg for the bimatoprost group and 16.3±3.7 mmHg for the LTFC group. No significant differences between the two treatment groups were found. As compared with baseline, mean IOP increased by 0.3±3.6 mmHg during the day and decreased by 0.8±3.8 mmHg during the night in the bimatoprost group, whereas there were increases of 1.43±2.6 mmHg during the day and 0.14±3.2 mmHg at night in the LTFC group.

The authors of the study concluded that bimatoprost is not inferior to LTFC in maintaining IOP at a controlled level during a 24-hour period in patients who switched from the non-fixed combination of latanoprost and timolol.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.